Compare Cardiovascular Benefits of SGLT2 Inhibitors for Type 2 Diabetes
January 2019
SGLT2 inhibitors (Invokana, etc) are in the spotlight again.
Reps will say Invokana (canagliflozin) is now approved to reduce risk of CV events in adults with type 2 diabetes and CV disease...while Jardiance (empagliflozin) is only approved to reduce CV death.
But Invokana's approval is based on NONsignificant reductions in CV death, MI, or stroke...lumped into one significant composite outcome.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote